"Contents" [2013] ELECD 841; in Drexl, Josef; Lee, Nari (eds), "Pharmaceutical Innovation, Competition and Patent Law" (Edward Elgar Publishing, 2013) v

Book Title: Pharmaceutical Innovation, Competition and Patent Law

Editor(s): Drexl, Josef; Lee, Nari

Publisher: Edward Elgar Publishing

ISBN (hard cover): 9780857932457

Section Title: Contents

Number of pages: 2

Extract:

Contents
List of contributors vii
Acknowledgments viii

Introduction 1
Nari Lee and Josef Drexl

PART I PATENT PROTECTION FOR PHARMACEUTICAL
METHODS

1. The patentability of genetic diagnostics in US law and policy 7
Rochelle C. Dreyfuss
2. Patentability of pharmaceutical innovations: the European
perspective 54
Rainer Moufang
3. Patentability of medical methods in Japan 85
Nari Lee

PART II DATA EXCLUSIVITY AND PATENT TERM EXTENSION:
CONVERGENCE OR DIVERGENCE

4. Patent term restoration and non-patent exclusivity in the US 111
Margo A. Bagley
5. Clinical data, data exclusivity and private investment protection in
Europe 141
Christian R. Fackelmann
6. Patent term extension in Japan: an academic and comparative
perspective 183
Ryoko Iseki
7. Recent UK case law on supplementary protection certificates 207
Richard Arnold
8. Patent term extension in Japan: focusing on the Pacif Capsule
decision 220
Toshiaki Imura



v
vi Pharmaceutical innovation, competition and patent law

PART III BALANCING INCENTIVES AND COMPETITION IN
EUROPE

9. Strategic patenting by the pharmaceutical industry: towards a
concept of abusive practices of protection 241
Hanns Ullrich
10. Anticompetitive marketing in the context of pharmaceutical
switching in Europe 273
Bengt Domeij
11. AstraZeneca and the EU sector inquiry: when do patent filings
violate competition law? 290
Josef Drexl

Index 323